Help for Alzheimer’s


Dr. Elliot Goldstein, President and CEO of ProMIS  Neurosciences, talks about their development in conquering Alzheimer’s disease.

Very simply put Alzheimer’s disease in terms of its economics and aside from all the heartbreak that goes with it, is it will bankrupt our healthcare systems in the next 10 years if we don’t solve this problem. Our company ProMIS Neurosciences is focused exclusively on neurodegenerative disease and particularly on developing precision medicine therapeutics for Alzheimer’s disease. First off we now understand as does the expert field the one of the root causes of Alzheimer’s disease is it bad actor protein which is a mis folded form of amyloid beta. Secondly, we’ve developed thermodynamic algorithms which are highly sophisticated techniques to identify specific sites on these bad actor protein and be able to neutralize or knock them out. Third the ProMis approach allows us to develop a best-in-class therapeutic. This is precision medicine because as we identify which target a patient has we give them the antibody specifically directed against that target. These are key bullets in addressing and ultimately conquering Alzheimer’s disease. Our lead product PMN 310 is moving forward and we expect to file an IMD which allows you to start your clinical trials by the end of 2018 so this is a major development for the company. We must find a solution to correct and stop this problem if not our healthcare systems will be bankrupt.

The company is based around the leading science of Dr. Neil Cashman, Professor of Medicine at the University of British Columbia, Neuroscientist at the Brain Research Center, and Academic Director of the Vancouver Coastal Hospital ALS Center. For over two decades, Neil Cashman has been among the leaders in the field of misfolded proteins (with over 300 publications and over 10,000 citations and 45 patent applications), and is one of several leading researchers of strain specific protein misfolding.

Based primarily on the research of ProMIS CSO, Dr. Neil Cashman, the Company has exclusive access to critical IP and proprietary know-how in the field. In addition, based on work from both Cashman’s lab, and ProMIS Chief Physics Officer, Steven Plotkin, ProMIS Neurosciences, Inc. utilizes two proprietary computational discovery technologies, ProMIS™ and Collective Coordinates, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. ProMIS™ Neurosciences has a broad patent estate granted relating to misfolded SOD1 in ALS and multiple patents submitted for disease specific epitopes (targets) on misfolded Amyloid beta in AD.

For more information on ProMIS Neurosciences (PMN.TO) please fill out the form below.

Request Investor Kit



Phone Number*